Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Rhea-AI Summary

Invivyd (Nasdaq: IVVD), a biopharmaceutical company, announced its inclusion in the Russell 2000® and Russell 3000® Indexes following the annual reconstitution. This is effective from today, July 1, 2024, at the opening of U.S. equity markets. Being part of the Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® or small-cap Russell 2000® Index and relevant growth and value style indexes. The Russell 3000® Index includes the 3,000 largest U.S.-traded stocks based on market capitalization and style attributes. Membership in these indexes is reviewed annually and helps investment managers and institutional investors benchmark active investment strategies and manage index funds. The Russell indexes are maintained by FTSE Russell, a leading global index provider.

Positive

• Invivyd's inclusion in the Russell 2000® and Russell 3000® Indexes may increase visibility among investors.
• Membership in these indexes could lead to increased stock demand from investment managers and institutional investors.

Negative

• None.

WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in the Russell 2000^® Index and the broad-market Russell 3000^® Index, effective at the open of U.S. equity markets today.

Membership in the Russell 3000^® Index means automatic inclusion in the large-cap Russell 1000^® Index or small-cap Russell 2000^® Index as well as in the appropriate growth and value style indexes. The Russell 3000^® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year.

The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 2000^® and Russell 3000^® Indexes and the Russell U.S. Indexes Reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website.

About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-0160
investors@invivyd.com

FAQ

What indexes has Invivyd been added to?

Invivyd has been added to the Russell 2000® and Russell 3000® Indexes.

When did Invivyd's inclusion in the Russell indexes become effective?

Invivyd's inclusion in the Russell indexes became effective on July 1, 2024.

How does Invivyd's inclusion in the Russell 3000® Index benefit the company?

Being part of the Russell 3000® Index increases Invivyd's visibility among investors and can result in higher stock demand from investment managers and institutional investors.

What is the significance of being included in the Russell 2000® Index for Invivyd?

Inclusion in the Russell 2000® Index signifies that Invivyd is recognized among the 2,000 largest small-cap U.S.-traded stocks, potentially boosting investor interest and stock liquidity.